Nexalin DIFS neurostimulation peer-reviewed study demonstrates improved attention and normalized brain activity in ADHD
Summary
Nexalin Technology published a peer-reviewed study in early 2026 demonstrating that their DIFS (Deep Intracranial Frequency Stimulation) transcranial neurostimulation improves attention and normalizes brain activity in patients with ADHD, as measured by quantitative EEG biomarkers. The study provides objective neurophysiological evidence — not just symptom rating scales — that Nexalin's electrical stimulation waveforms modulate the deep brain circuits associated with attention regulation. The ADHD indication joins Nexalin's anxiety applications in a non-invasive neurostimulation platform targeting common, high-prevalence psychiatric conditions.
Why it matters
A peer-reviewed ADHD study with qEEG biomarker evidence of attention normalization positions Nexalin as having objective mechanistic evidence beyond symptomatic improvement scores. With stimulant medication shortages, parent concerns about long-term stimulant use in children, and large adult ADHD populations seeking non-pharmacological alternatives, a non-invasive FDA-cleared device with published brain biomarker data could find rapid commercial uptake.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial